KANSAS CITY, Mo., May 4 /PRNewswire-USNewswire/ -- Recognized internationally for its expertise in virology and toxicology, Midwest Research Institute (MRI) has been selected by PATH to support its vaccine partner companies in advancing the development of new, safe, and effective influenza vaccines. The goal of the PATH effort is to produce vaccines more quickly, economically, and in large quantities to counter a global influenza pandemic.
MRI, headquartered in Kansas City, is one of the nation's leading independent scientific organizations conducting contract research for government, industry and academia since 1944.
PATH, an international, nonprofit organization, creates sustainable, culturally relevant solutions that enable communities worldwide to break longstanding cycles of poor health. In 2008, PATH launched a vaccine research program to accelerate influenza vaccine development through partnerships with public- and private-sector organizations.
Through the agreement, PATH partner companies will contract with MRI to perform assays and preclinical studies using influenza vaccine candidates. These studies will include in-vivo and in-vitro experiments, animal safety studies, and chemistry support activities. PATH strives to consolidate and standardize the preclinical animal testing at a single source, MRI, to improve consistency of study performance and reliability and reproducibility of associated data for their partnering companies.
"The opportunity to support PATH in their mission to improve world health is an exceptional achievement for MRI," said Thomas Sack, Ph.D., MRI Regional Vice President of Midwest Operations. "Our selection by PATH is recognition of MRI's excellence in biological and health sciences and our outstanding vaccine development and influenza virus testing programs."
About Midwest Research Institute<
|SOURCE Midwest Research Institute|
Copyright©2009 PR Newswire.
All rights reserved